IL243488A0 - Compounds, compositions and methods for making dihydroxyphenyl neurotransmitter - Google Patents
Compounds, compositions and methods for making dihydroxyphenyl neurotransmitterInfo
- Publication number
- IL243488A0 IL243488A0 IL243488A IL24348816A IL243488A0 IL 243488 A0 IL243488 A0 IL 243488A0 IL 243488 A IL243488 A IL 243488A IL 24348816 A IL24348816 A IL 24348816A IL 243488 A0 IL243488 A0 IL 243488A0
- Authority
- IL
- Israel
- Prior art keywords
- dihydroxyphenyl
- compositions
- methods
- neurotransmitter
- compounds
- Prior art date
Links
- -1 Dihydroxyphenyl Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000002858 neurotransmitter agent Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361843549P | 2013-07-08 | 2013-07-08 | |
| US201462010098P | 2014-06-10 | 2014-06-10 | |
| PCT/US2014/045731 WO2015006315A1 (en) | 2013-07-08 | 2014-07-08 | Dihydroxyphenyl neurotransmitter compounds, compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL243488A0 true IL243488A0 (en) | 2016-02-29 |
Family
ID=52133230
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL243488A IL243488A0 (en) | 2013-07-08 | 2016-01-05 | Compounds, compositions and methods for making dihydroxyphenyl neurotransmitter |
| IL266767A IL266767A (en) | 2013-07-08 | 2019-05-21 | Compounds, compositions and methods for making dihydroxyphenyl neurotransmitter |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL266767A IL266767A (en) | 2013-07-08 | 2019-05-21 | Compounds, compositions and methods for making dihydroxyphenyl neurotransmitter |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US20150011630A1 (enExample) |
| EP (2) | EP3611159B1 (enExample) |
| JP (1) | JP6567515B2 (enExample) |
| KR (1) | KR20160041912A (enExample) |
| CN (1) | CN105473545B (enExample) |
| AU (2) | AU2014287418A1 (enExample) |
| BR (1) | BR112016000338A8 (enExample) |
| CA (1) | CA2917159C (enExample) |
| CL (1) | CL2016000019A1 (enExample) |
| EA (1) | EA201600093A1 (enExample) |
| HK (1) | HK1221713A1 (enExample) |
| IL (2) | IL243488A0 (enExample) |
| MX (1) | MX384131B (enExample) |
| PE (1) | PE20160556A1 (enExample) |
| SG (2) | SG10201800166UA (enExample) |
| WO (1) | WO2015006315A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3032168C (en) * | 2016-08-30 | 2020-04-21 | Theravance Biopharma R&D Ip, Llc | Compound for use in the treatment of neurogenic orthostatic hypotension |
| GB2566516A (en) | 2017-09-15 | 2019-03-20 | Univ Oxford Innovation Ltd | Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US10947196B2 (en) | 2019-03-27 | 2021-03-16 | Curasen Therapeutics, Inc. | Beta adrenergic agonist and methods of using the same |
| KR20220008824A (ko) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| US20220401415A1 (en) * | 2019-10-25 | 2022-12-22 | Curasen Therapeutics, Inc. | Methods for treating neurological disorders with alpha1a-ar partial agonists |
| US11607395B2 (en) | 2019-12-18 | 2023-03-21 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
| WO2021247963A1 (en) * | 2020-06-05 | 2021-12-09 | Senda Biosciences, Inc. | (s)-alpha-fluoromethyltyrosine as decarboxylase inhibitors for use in the treatment of hypotension |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0084928B1 (en) * | 1982-01-14 | 1985-09-11 | Sumitomo Chemical Company, Limited | Process for producing threo-3-(3,4-dihydroxyphenyl)serine |
| CA1223602A (en) | 1983-05-25 | 1987-06-30 | Naohito Ohashi | Process for producing 3-(3,4-dihydroxyphenyl) serine |
| JP3764179B2 (ja) | 1994-07-05 | 2006-04-05 | 克寛 西野 | 運動・意識または言語障害の機能改善剤 |
| DE19619510A1 (de) | 1995-05-18 | 1996-11-21 | Sumitomo Chemical Co | Verfahren zur Herstellung von Threo-3-(3,4-dihydroxyphenyl)serin |
| JP3489319B2 (ja) | 1996-03-12 | 2004-01-19 | 住友化学工業株式会社 | カルボン酸誘導体、その製造法および用途 |
| JPH115738A (ja) | 1997-06-15 | 1999-01-12 | Katsuhiro Nishino | 脳虚血に伴う神経脱落症状の予防剤および超急性期治療剤 |
| US6376531B1 (en) * | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| DE10261807A1 (de) * | 2002-12-19 | 2004-07-01 | Turicum Drug Development Ag | Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel |
| WO2005084330A2 (en) | 2004-03-02 | 2005-09-15 | Synergia Pharma, Inc. | Compositions and methods for treating nasal congestion |
| BRPI0708071A8 (pt) * | 2006-02-17 | 2017-12-26 | Birds Pharma Gmbh Berolina Innovative Res & Development Services | Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos |
| AU2008226541B2 (en) | 2007-03-09 | 2013-05-09 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia |
| US20080227830A1 (en) * | 2007-03-12 | 2008-09-18 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension |
| ES2431570T3 (es) | 2007-05-07 | 2013-11-27 | Chelsea Therapeutics, Inc. | Droxidopa y composición farmacéutica de la misma para el tratamiento de los trastornos por déficit de atención |
| WO2008151179A2 (en) | 2007-06-04 | 2008-12-11 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines |
| US20100172916A1 (en) * | 2008-11-10 | 2010-07-08 | Auspex Pharmaceuticals, Inc. | Substituted hydroxyphenylamine compounds |
| US9072730B2 (en) | 2009-05-14 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognitive functions in individuals with down syndrome and/or alzheimer's disease |
| WO2011001976A1 (ja) | 2009-07-01 | 2011-01-06 | 大日本住友製薬株式会社 | スレオ－３－（３，４－ジヒドロキシフェニル）－ｌ－セリンの製造法 |
| JP5880913B2 (ja) | 2011-05-17 | 2016-03-09 | 三郎 佐古田 | パーキンソン病の体幹症状（姿勢反射異常）の治療剤 |
| US20130253061A1 (en) | 2012-03-20 | 2013-09-26 | Chelsea Therapeutics, Inc. | Method of droxidopa synthesis |
-
2014
- 2014-07-08 AU AU2014287418A patent/AU2014287418A1/en not_active Abandoned
- 2014-07-08 EP EP19188210.9A patent/EP3611159B1/en active Active
- 2014-07-08 HK HK16109787.0A patent/HK1221713A1/zh unknown
- 2014-07-08 CN CN201480042918.0A patent/CN105473545B/zh not_active Expired - Fee Related
- 2014-07-08 KR KR1020167003133A patent/KR20160041912A/ko not_active Withdrawn
- 2014-07-08 SG SG10201800166UA patent/SG10201800166UA/en unknown
- 2014-07-08 SG SG11201510764QA patent/SG11201510764QA/en unknown
- 2014-07-08 WO PCT/US2014/045731 patent/WO2015006315A1/en not_active Ceased
- 2014-07-08 EP EP14822407.4A patent/EP3019467A4/en not_active Withdrawn
- 2014-07-08 MX MX2016000219A patent/MX384131B/es unknown
- 2014-07-08 CA CA2917159A patent/CA2917159C/en active Active
- 2014-07-08 JP JP2016525422A patent/JP6567515B2/ja not_active Expired - Fee Related
- 2014-07-08 BR BR112016000338A patent/BR112016000338A8/pt not_active Application Discontinuation
- 2014-07-08 EA EA201600093A patent/EA201600093A1/ru unknown
- 2014-07-08 PE PE2016000010A patent/PE20160556A1/es unknown
- 2014-07-08 US US14/325,988 patent/US20150011630A1/en not_active Abandoned
-
2016
- 2016-01-05 IL IL243488A patent/IL243488A0/en unknown
- 2016-01-07 CL CL2016000019A patent/CL2016000019A1/es unknown
-
2017
- 2017-07-21 US US15/656,035 patent/US20170319694A1/en not_active Abandoned
-
2018
- 2018-06-06 US US16/000,965 patent/US20180280511A1/en not_active Abandoned
- 2018-10-26 AU AU2018253594A patent/AU2018253594A1/en not_active Abandoned
-
2019
- 2019-05-21 IL IL266767A patent/IL266767A/en unknown
- 2019-08-01 US US16/529,187 patent/US20190374642A1/en not_active Abandoned
-
2021
- 2021-08-11 US US17/399,708 patent/US20220072131A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL266767A (en) | 2019-07-31 |
| CN105473545B (zh) | 2017-08-04 |
| WO2015006315A1 (en) | 2015-01-15 |
| MX384131B (es) | 2025-03-14 |
| US20190374642A1 (en) | 2019-12-12 |
| HK1216747A1 (zh) | 2016-12-02 |
| US20180280511A1 (en) | 2018-10-04 |
| BR112016000338A8 (pt) | 2020-01-07 |
| JP2016529228A (ja) | 2016-09-23 |
| CA2917159A1 (en) | 2015-01-15 |
| AU2014287418A1 (en) | 2016-01-28 |
| AU2018253594A1 (en) | 2018-11-22 |
| US20220072131A1 (en) | 2022-03-10 |
| SG10201800166UA (en) | 2018-02-27 |
| EA201600093A1 (ru) | 2016-08-31 |
| EP3611159A1 (en) | 2020-02-19 |
| CN105473545A (zh) | 2016-04-06 |
| PE20160556A1 (es) | 2016-06-11 |
| EP3019467A1 (en) | 2016-05-18 |
| KR20160041912A (ko) | 2016-04-18 |
| US20170319694A1 (en) | 2017-11-09 |
| EP3611159B1 (en) | 2023-01-25 |
| JP6567515B2 (ja) | 2019-08-28 |
| MX2016000219A (es) | 2016-05-31 |
| CA2917159C (en) | 2022-08-23 |
| HK1221713A1 (zh) | 2017-06-09 |
| BR112016000338A2 (pt) | 2017-08-22 |
| EP3019467A4 (en) | 2017-03-15 |
| CL2016000019A1 (es) | 2016-11-04 |
| US20150011630A1 (en) | 2015-01-08 |
| SG11201510764QA (en) | 2016-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201601138PA (en) | Certain chemical entities, compositions, and methods | |
| PL3065569T4 (pl) | Kompozycja | |
| IL241355B (en) | Pyrazole-amide compounds, preparations containing them and their uses | |
| IL266767A (en) | Compounds, compositions and methods for making dihydroxyphenyl neurotransmitter | |
| PL3027750T3 (pl) | Kompozycja biokatalityczna | |
| GB201319540D0 (en) | Composition | |
| GB201318489D0 (en) | Composition | |
| EP3006525A4 (en) | ASPHALT-URETHANE COMPOSITION | |
| GB201320919D0 (en) | Composition | |
| GB201320303D0 (en) | Composition | |
| GB201317388D0 (en) | Composition | |
| SG11201507608PA (en) | Toxoid, compositions and related methods | |
| GB201319538D0 (en) | Composition | |
| GB201306984D0 (en) | Composition | |
| IL243778A0 (en) | Combined immune complexes | |
| ZA201600015B (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| GB201322456D0 (en) | Radiotracer compositions and methods | |
| GB201322772D0 (en) | Composition | |
| GB201317196D0 (en) | Composition | |
| GB201307622D0 (en) | Composition | |
| PT3066199T (pt) | Snorna, composições e utilizações | |
| SG11201507578PA (en) | Toxoid, compositions and related methods | |
| GB201420672D0 (en) | Composition | |
| GB201308502D0 (en) | Composition | |
| GB201301774D0 (en) | Composition |